Inpact - Preclinical Pharmacology Service
Establishing proof of concept in preclinical pharmacology is a critical step in the drug discovery process. This is one of the decisive factors in setting the therapeutic indication(s) targeted in clinical models and in the decision to continue a new product through the regulatory preclinical and clinical steps. For more than 25 years, Oncodesign has been a player known for its experience and excellence in preclinical pharmacology, particularly in vitro and in vivo testing, PK, PK/PD relationships and pharmaco-imaging applied to the identification and qualification of the therapeutic potential of many different approaches and techniques – chemical entities, peptides, oligonucleotides, biologics, gene and cell therapies, oncolytic viruses, vaccines and more.
A Partnership Of Choice For Your Therapeutic Innovation
INPACT is an integrated service in preclinical pharmacology to support you and bring our expertise in guiding and establishing proof of concept for your therapeutic discovery and innovation programs in oncology, immuno-inflammation and COVID-19 pathology.
INPACT – Oncology, a continuum of expertise in anti-cancer pharmacology and immuno-oncology, developed within our technical innovation platforms TOT® (phenotyping), Predict® – Oncology (syngeneic, CDX, chemo-induced models), Chi-mice® (humanized models, PDX), Pharmimage® (in vivo pharmaco-imaging), combined with our DMPK and bioanalysis capabilities.
INPACT – Inflammation, a broad range of pharmacological expertise in in vitro and in vivo models of acute or chronic inflammation, as well as fibrosis, for many organs, developed within our technical innovation platform Predict® – Inflammatory diseases, et and combined with our DMPK and bioanalysis capabilities.
INPACT – Covid-19, an extensive in vitro and in vivo preclinical pharmacological evaluation of SARS-CoV-2 infection in rodent and non-human primate models, combined with our DMPK and bioanalysis capabilities.